The safety and efficacy of EBV specific cytotoxic T cell in patients with EBV positive post-transplant lymphoproliferative disease

The Catholic University of Korea, Seoul St. Mary's Hospital0 sites2 target enrollmentStarted: TBDLast updated: March 11, 2019

Conditions

Trial Snapshot

No summary available.

•Patients matching all of the following were included:
•1)Histologically verified PTLD patient according to the World Health Organization (WHO) classification
•2) Patients who showed response to conventional therapy of PTLD, including reduction of immunosuppression, chemotherapy, surgery, and/or radiotherapy
•3)Patients who are at least 14 years old up to 74 years old
•4) Eastern Cooperative Oncology Group (ECOG) performance rating of 0, 1, 2
•5) Patients with adequate kidney function (serum creatinine less than 1.5 times the normal upper limit)
•6) Patients with adequate liver function (bilirubin less than 1.5 times the normal upper limit in the serum)
•7) Patients with adequate heart function (there should be no specific electrocardiographic findings according to the principal investigator's judgment)
•8) No evidence of secondary tumor, heart failure, infection chronic lung disease ultimately according to the principal investigator's judgment.
•9) Voluntarily signed the informed patient consent

•Patients with any of the following were excluded from the study:
•1) Pregnancy, lactation or potential of pregnancy
•2) Bacterial or fungal infection of unknown cause or patients with fever (=38?) or active infection in progress
•3) Patients under 14 years old or over 75 years old
•4) Eastern Cooperative Oncology Group (ECOG) performance rating of 3, 4
•5) Previously demonstrated human immunodeficiency virus (HIV) infection, hypertension (diastolic blood pressure >115mmHg), unstable angina, congestive heart failure (NY class II or higher), severe diabetes that is not well controlled, coronary angioplasty within the last 6 months, patients with acute myocardial infarction or non-malignant diseases including atrial ventricular arrhythima within the past six months
•6)Patients with a mental disorder or substance abuse that is considered to affect the results of the research
•7) Patients participating in another clinical trial
•8) Patients with other serious medical conditions.
•9) Patients who did not achieve complete response following inital therapy, including chemotherapy and/or radiotherapy, salvage therapy, or high-dose therapy and stem cell transplantation.

Sponsor

The Catholic University of Korea, Seoul St. Mary's Hospital